Market Research Report
Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||363567|
|Published||Content info||58 Pages
Delivery time: 1-2 business days
|Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019|
|Published: December 27, 2019||Content info: 58 Pages||
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Treatment Resistant Depression, Depression, Drug Addiction, Psychosis, Anxiety Disorders, Dementia, Dementia Associated With Alzheimer's Disease, Epilepsy, Ischemia, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Post-Traumatic Stress Disorder (PTSD) and Stroke.
The latest report Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.